Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Basso StephenOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,899Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Basso StephenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,096Price:$14.88
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Ronsheim MatthewOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,338Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Ronsheim MatthewOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,768Price:$14.88
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Zhen MarianneOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,022Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Zhen MarianneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,752Price:$14.88
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Raifeld PavelOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Raifeld PavelOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Raifeld PavelOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Ronsheim MatthewOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-807Price:$15.80
Filings by filing date
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Basso StephenOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:25,899Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Basso StephenOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,096Price:$14.88
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Ronsheim MatthewOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:27,338Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Ronsheim MatthewOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,768Price:$14.88
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Zhen MarianneOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:23,022Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Zhen MarianneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10,752Price:$14.88
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Raifeld PavelOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Raifeld PavelOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Raifeld PavelOwnership Type:Direct OwnershipSecurities:Non-statutory Stock OptionNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Feb 20, 2024 (filed on Feb 22, 2024)Insider Name:Ronsheim MatthewOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-807Price:$15.80
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1350 OLD BAYSHORE HIGHWAY, SUITE 400 BURLINGAME CA 94010 |
Tel: | N/A |
Website: | https://www.inva.com |
IR: | See website |
Key People | ||
Pavel Raifeld Chief Executive Officer | Stephen Basso Chief Financial Officer | Marianne Y. Zhen Chief Accounting Officer |
Business Overview |
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI). |
Financial Overview |
For the fiscal year ended 31 December 2023, Innoviva Inc revenues decreased 6% to $310.5M. Net income decreased 16% to $179.7M. Revenues reflect Revenue decrease of 23% to $238.8M. Net income also reflects Gain on TRC sale decrease from $266.7M (income) to $0K, General and administrative increase of 61% to $93.6M (expense), Total Amort of Intangibles-excl Goodwill increase from $5.6M to $21.8M (expense). |
Employees: | 112 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,212M as of Dec 31, 2023 |
Annual revenue (TTM): | $310.46M as of Dec 31, 2023 |
EBITDA (TTM): | $149.59M as of Dec 31, 2023 |
Net annual income (TTM): | $179.72M as of Dec 31, 2023 |
Free cash flow (TTM): | $140.65M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $252.72M as of Dec 31, 2023 |
Shares outstanding: | 63,227,333 as of Feb 14, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |